ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Closed 11-13 16:00:00 EST

0.9100

-0.0536

-5.56%

盘后0.9700

+0.0600+6.59%

19:12 EST

High0.9800	Low0.8610	Vol38.18K
Open0.9700	D1 Closing0.9636	Amplitude12.35%
Mkt Cap24.55M	Tradable Cap20.16M	Total Shares26.98M
T/O34.73K	T/O Rate0.17%	Tradable Shares22.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":0.91,"timestamp":1794603600000,"preClose":0.9636,"halted":0,"volume":38178,"hourTrading":{"tag":"盘后","latestPrice":0.97,"preClose":0.91,"latestTime":"19:12 EST","volume":1823,"amount":1768.291,"timestamp":1794615135332,"change":0.06,"changeRate":0.065934,"amplitude":0.071978},"delay":0,"changeRate":-0.05562474055624739,"floatShares":22148500,"shares":26976625,"eps":-0.152165,"marketStatus":"Closed","change":-0.0536,"latestTime":"11-13 16:00:00 EST","open":0.97,"high":0.98,"low":0.861,"amount":34733.49073992,"amplitude":0.123495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.152165,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":5,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":0.9636,"postHourTrading":{"tag":"盘后","latestPrice":0.97,"preClose":0.91,"latestTime":"19:12 EST","volume":1823,"amount":1768.291,"timestamp":1794615135332,"change":0.06,"changeRate":0.065934,"amplitude":0.071978},"volumeRatio":1.443468,"impliedVol":0.4964,"impliedVolPercentile":0.3426},"requestUrl":"/m/hq/s/ABVC","defaultTab":"news","newsList":[{"id":"2683568569","title":"Press Release: Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2683568569","media":"Dow Jones","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683568569?lang=en_us&edition=fundamental","pubTime":"2026-11-14 05:45","pubTimestamp":1794606300,"startTime":"0","endTime":"0","summary":"Manufacturing Work Addressing FDA CMC Information Requests Substantially CompletedNDA Resubmission Expected Between December 2026 and January 2027KANSAS CITY, Kan., Nov. 13, 2026 (GLOBE NEWSWIRE) -- C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2746668974.SGD","LU0128526141.USD","BK4588","LU0267386448.USD","CDMO","EES","BK4099","BK4604","IE00BHPRN162.USD","BK4139","BK7095","IE00BZ1G4Q59.USD","BK4006","LU2237443465.HKD","IE00B1BXHZ80.USD","LU0757428866.USD","LU2237443622.USD","CMC","LU0149725797.USD","IE00BFMHRM44.USD","LU0029874061.USD","LU0390134368.USD","LU2746668461.USD","LU2237443978.SGD","CRL.AU","BK4121","LU2237443382.USD","LABU","TM","BK4555","BK4530","LU0170899867.USD","LU1363072403.SGD","IE00BFXG1179.USD","03160","IE00BKVL7J92.USD","LU0971096721.USD","BK4585","LU2237443549.SGD","CING","BK4007","LU2237443895.HKD","LU0234572021.USD","LU0882574139.USD","ADHD","ABVC","LU1815336091.USD","CMC.AU","CRL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682180613","title":"Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King","url":"https://stock-news.laohu8.com/highlight/detail?id=2682180613","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682180613?lang=en_us&edition=fundamental","pubTime":"2026-11-10 21:00","pubTimestamp":1794315600,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., Nov.  10, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform to devel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/10/3399411/0/en/shane-schaffer-cingulate-chairman-and-ceo-provides-update-on-ctx-1301-in-interview-with-innovators-with-jane-king.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","SEC.AU","ABVC","BK4007","CING","BK4139","032820.KR","BK9077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682339381","title":"Press Release: Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2682339381","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682339381?lang=en_us&edition=fundamental","pubTime":"2026-11-10 05:01","pubTimestamp":1794258060,"startTime":"0","endTime":"0","summary":"study in GAD with 214 participants randomized 1:1 to receive DT120 ODT. --  Met the primary endpoint and all key secondary efficacy. endpoints with a high degree of statistical significance.meaningful placebo-adjusted improvement of 5.4 points in Hamilton. Anxiety Rating Scale  total score from baseline at Week 12. --  DT120 ODT was generally well tolerated, with no drug-related. serious adverse events and no suicidality signal observed in Part. --  DT120 ODT in GAD: Reported positive topline results from P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD","DFTX","BK4007","BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681185778","title":"Collegium Pharmaceutical Earnings Call Highlights ADHD Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2681185778","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681185778?lang=en_us&edition=fundamental","pubTime":"2026-11-07 08:25","pubTimestamp":1794011154,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical Inc. (($COLL)) has held its Q3 earnings call. Read on for the main highlights of the call. Collegium Pharmaceutical’s earn...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/collegium-pharmaceutical-earnings-call-highlights-adhd-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/collegium-pharmaceutical-earnings-call-highlights-adhd-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681384895","title":"Axsome Advances Adolescent ADHD Study as Investors Await Solriamfetol Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2681384895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681384895?lang=en_us&edition=fundamental","pubTime":"2026-11-07 00:33","pubTimestamp":1793982786,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Study Overview: Axsome Therapeutics, Inc. is studying solriam...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/axsome-advances-adolescent-adhd-study-as-investors-await-solriamfetol-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/axsome-advances-adolescent-adhd-study-as-investors-await-solriamfetol-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","ABVC","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681323862","title":"Collegium’s Belbuca Resilience and ADHD Growth Support Buy Rating; $60 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2681323862","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681323862?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:59","pubTimestamp":1793973543,"startTime":"0","endTime":"0","summary":"Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Collegium Pharmaceutical. The associated price target remains the sam...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/collegiums-belbuca-resilience-and-adhd-growth-support-buy-rating-60-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/collegiums-belbuca-resilience-and-adhd-growth-support-buy-rating-60-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRTO","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681197858","title":"Yukiguni Maitake Sees FY Net Y2.54b","url":"https://stock-news.laohu8.com/highlight/detail?id=2681197858","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681197858?lang=en_us&edition=fundamental","pubTime":"2026-11-06 15:51","pubTimestamp":1793951460,"startTime":"0","endTime":"0","summary":"Yukiguni Maitake Co. Ltd. also released the following forecasts:. Results are based on IFRS accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680766826","title":"Wallachbeth Capital Announces ABVC Biopharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680766826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680766826?lang=en_us&edition=fundamental","pubTime":"2026-11-02 23:00","pubTimestamp":1793631601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUAF8K21:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680576576","title":"ABVC BioPharma Closes Senior Convertible Note Offering, Raising $3.39 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680576576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680576576?lang=en_us&edition=fundamental","pubTime":"2026-11-02 22:52","pubTimestamp":1793631131,"startTime":"0","endTime":"0","summary":"ABVC BioPharma closes senior convertible note offering, raising $3.39 millionABVC BioPharma closed a private placement of original issue discount senior convertible promissory notes, raising approximately $3.39 million gross.The notes carry a 17.5% original issue discount, with $4.11 million aggregate principal maturing June 30, 2027.Net proceeds will fund working capital, subsidiaries and a $625,000 settlement payment to Lind Global Fund II LP.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 02, 2026, and is solel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL5vRKfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679263401","title":"Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts","url":"https://stock-news.laohu8.com/highlight/detail?id=2679263401","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679263401?lang=en_us&edition=fundamental","pubTime":"2026-10-29 20:00","pubTimestamp":1793275200,"startTime":"0","endTime":"0","summary":"New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families. Working to make soccer more accessible through an adaptive soccer clinic.Providing tools to coach children with neurodivergent conditions like ADHD. child experiencing the adaptive soccer clinic from Oct. 24, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/29/3391167/34897/en/collegium-pharmaceutical-and-boston-legacy-fc-expand-their-partnership-beyond-matchday-to-communities-across-massachusetts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDC","BK4135","CNS","ADHD","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679144387","title":"BlinkLab Advances ADHD Diagnostic Platform and U.S. FDA Pathway for Autism Tool","url":"https://stock-news.laohu8.com/highlight/detail?id=2679144387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679144387?lang=en_us&edition=fundamental","pubTime":"2026-10-29 06:52","pubTimestamp":1793227952,"startTime":"0","endTime":"0","summary":"An update from Blinklab Limited ( ($AU:BB1) ) is now available. BlinkLab reported that its first European ADHD case-control study in children deliv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blinklab-advances-adhd-diagnostic-platform-and-u-s-fda-pathway-for-autism-tool?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blinklab-advances-adhd-diagnostic-platform-and-u-s-fda-pathway-for-autism-tool?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","BK4585","ABVC","BK4588","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677671330","title":"Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2677671330","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677671330?lang=en_us&edition=fundamental","pubTime":"2026-10-21 20:30","pubTimestamp":1792585800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Oct.  21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar TMS technology with direct patient care through ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/21/3385514/0/en/neuronetics-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ABVC","TMS","BK4176","STIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677676760","title":"Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2677676760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677676760?lang=en_us&edition=fundamental","pubTime":"2026-10-21 20:00","pubTimestamp":1792584000,"startTime":"0","endTime":"0","summary":"Seven presentations include pediatric Phase 4 studies of AZSTARYS (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM (Delayed-Release/Extended-Release Methylphenidate)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/21/3385443/34897/en/collegium-to-present-pediatric-and-real-world-research-across-adhd-portfolio-at-aacap-and-nei-fall-congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","ABVC","RSHO","POW","ADHD","BK4588","BK4135","BK4139","BK4585","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675452713","title":"Seaport Therapeutics initiated with a Buy at Canaccord on MDD potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2675452713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675452713?lang=en_us&edition=fundamental","pubTime":"2026-10-14 18:50","pubTimestamp":1791975056,"startTime":"0","endTime":"0","summary":"As previously reported, Canaccord analyst Sumant Kulkarni initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $28 price target ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-initiated-with-a-buy-at-canaccord-on-mdd-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-initiated-with-a-buy-at-canaccord-on-mdd-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","SPTX","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674866345","title":"Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866345","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866345?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:32","pubTimestamp":1791567135,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical (COLL) should benefit from continued strength in its attention-deficit/hyperactivity disorder drugs, limited near-term generic risk for Belbuca and stable pricing trends, whil","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU1983299246.USD","BK4557","BK4566","BK4584","TEVA","COLL","BK4596","BK4007","LU2324357040.USD","ABVC","BK4588","BK4559","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011796","title":"Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011796?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390650,"startTime":"0","endTime":"0","summary":"Alkermes plc ($ALKS) announced an update on their ongoing clinical study. Alkermes plc (ALKS) is running a mid-stage clinical study to test a new A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBRN","MEDX","PSIL","FBT","ALKS","PSCH","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673205650","title":"Collegium Launches \"Start Talking ADHD\" with Practical Support to Help Families Navigate Care, School and Everyday Life","url":"https://stock-news.laohu8.com/highlight/detail?id=2673205650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673205650?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288000,"startTime":"0","endTime":"0","summary":"New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical settingSTOUGHTON, Mass., Oct.  06, 2026 (GLOBE NEWSWIRE) -- Collegium","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375438/34897/en/collegium-launches-start-talking-adhd-with-practical-support-to-help-families-navigate-care-school-and-everyday-life.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","ADHD","BK4206","IEP","BK4590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669745486","title":"Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2669745486","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669745486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168400,"startTime":"0","endTime":"0","summary":"One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinicsVANCOUVER, British Columbia, Sept.  23, 2026 (GLOB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367523/0/en/optimi-health-completes-psilocybin-production-for-health-canada-approved-phase-2-mdd-trial-and-commercial-trd-supply.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OPTH","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412748","title":"Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412748","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412748?lang=en_us&edition=fundamental","pubTime":"2026-09-23 05:08","pubTimestamp":1790111297,"startTime":"0","endTime":"0","summary":"Aytu BioPharma’s fiscal Q4 2026 net revenue rose 6.4% to $16.1 million, while diluted net loss per share improved to $0.00 from $2.92 a year earlier. EXXUA generated $3.9 million in its first full launch quarter and helped offset declines in the ADHD and Pediatric portfolios. Gross margin narrowed to 64.6% from 67.8%, and adjusted EBITDA fell to $0.5 million from $2.0 million as commercialization spending increased. The company ended June 30, 2026 with $26.3 million in cash, down from $31.0 million a year earlier.","market":"other","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock1.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock1.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262181336-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ABVC","AYTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669232251","title":"Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669232251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669232251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:39","pubTimestamp":1790091552,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's confidence in ALKS7290 and reinforced the potential of its broader \"orexin pipeline,\" RBC Capital Market","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","MEDX","FBT","BK4139","PSCH","ABVC","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":-0.0157},{"period":"3month","weight":0.0708},{"period":"6month","weight":-0.116},{"period":"1year","weight":-0.6777},{"period":"ytd","weight":-0.5476}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.375,"avgChangeRate":1.167092},{"month":7,"riseRate":0.375,"avgChangeRate":-0.130229},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.065211},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.032147},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.065885},{"month":11,"riseRate":0.555556,"avgChangeRate":0.041696},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction